

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**AIM Vaccine Co., Ltd.**  
**艾美疫苗股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 06660)**

**VOLUNTARY ANNOUNCEMENT**  
**APPLICATION FOR CLINICAL TRIAL OF THE ITERATIVE-PROCESS**  
**HIGHLY-EFFECTIVE HUMAN DIPLOID RABIES VACCINE**

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company of the latest business developments of the Group.

The application for clinical trial of the iterative-process highly-effective human diploid rabies vaccine developed by the Group has been submitted to the Center for Drug Evaluation (CDE) of National Medical Products Administration of China recently.

Rabies is the most deadly disease in the world, with a fatality rate of nearly 100%. Currently, there is a lack of effective treatment for rabies in clinical practice, therefore, post-exposure prevention is crucial, and the main preventive measure is vaccination against human rabies. There are two kinds of rabies vaccines, namely the serum-containing rabies vaccine and the serum-free rabies vaccine. However, no serum-free rabies vaccine has been registered or marketed yet. The mainstream Vero cell rabies vaccine and human diploid rabies vaccine currently available in the market are serum-containing rabies vaccines.

Compared with the traditional Vero cell rabies vaccines, human diploid rabies vaccine uses human diploid cells instead of Vero cells, which are homologous to humans and have a natural safety advantage. The human diploid rabies vaccine currently available in the market is 3 to 5 times more expensive than the Vero cell rabies vaccine, with higher product added value.

Compared with the traditional human diploid rabies vaccines of the first generation, the iterative-process highly-effective human diploid rabies vaccine developed by the Group has taken the lead in breaking through the technical bottlenecks of low virus titer and low yield in the traditional process. It has been optimized and innovated in the purification process with the product quality and safety significantly improved.

Compared with the number of traditional rabies vaccinations, this product developed by the Group can be vaccinated with either “five-needle approach”, “simple four-needle approach” or “2-1-1 four-needle approach”, which is more flexible and convenient.

The Group has completed the construction of an iterative-process high-efficiency human diploid rabies vaccine workshop that meets international standards, and has completed the production of commercial-scale Phase III clinical trial samples, which is capable of producing this product in large scale.

As the world’s second largest supplier of rabies vaccines, the Group is committed to leading the in-depth technology iteration and upgrading of rabies vaccines globally and providing the market with a series of rabies vaccine products with better quality and higher safety, thereby promoting the sustainable development of the Company.

By order of the Board  
**AIM Vaccine Co., Ltd.**  
**Mr. Yan ZHOU**

*Chairman of the Board, Executive Director and  
Chief Executive Officer*

Hong Kong, November 7, 2024

*As at the date of this announcement, the Board of the Company comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Wen GUAN, Mr. Shaojun JIA and Mr. Jie ZHOU as executive directors; Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Hui OUYANG, Ms. Jie WEN and Mr. Xiaoguang GUO as independent non-executive directors.*